Literature DB >> 24648459

Within-host evolution results in antigenically distinct GII.4 noroviruses.

Kari Debbink1, Lisa C Lindesmith2, Martin T Ferris3, Jesica Swanstrom2, Martina Beltramello4, Davide Corti5, Antonio Lanzavecchia6, Ralph S Baric7.   

Abstract

UNLABELLED: Genogroup II, genotype 4 (GII.4) noroviruses are known to rapidly evolve, with the emergence of a new primary strain every 2 to 4 years as herd immunity to the previously circulating strain is overcome. Because viral genetic diversity is higher in chronic than in acute infection, chronically infected immunocompromised people have been hypothesized to be a potential source for new epidemic GII.4 strains. However, while some capsid protein residues are under positive selection and undergo patterned changes in sequence variation over time, the relationships between genetic variation and antigenic variation remains unknown. Based on previously published GII.4 strains from a chronically infected individual, we synthetically reconstructed virus-like particles (VLPs) representing early and late isolates from a small-bowel transplant patient chronically infected with norovirus, as well as the parental GII.4-2006b strain. We demonstrate that intrahost GII.4 evolution results in the emergence of antigenically distinct strains over time, comparable to the variation noted between the chronologically predominant GII.4 strains GII.4-2006b and GII.4-2009. Our data suggest that in some individuals the evolution that occurs during a chronic norovirus infection overlaps with changing antigenic epitopes that are associated with successive outbreak strains and may select for isolates that are potentially able to escape herd immunity from earlier isolates. IMPORTANCE: Noroviruses are agents of gastrointestinal illness, infecting an estimated 21 million people per year in the United States alone. In healthy individuals, symptomatic infection typically resolves within 24 to 48 h. However, symptoms may persist for years in immunocompromised individuals, and development of successful treatments for these patients is a continuing challenge. This work is relevant to the design of successful norovirus therapeutics for chronically infected patients; provides support for previous assertions that chronically infected individuals may serve as reservoirs for new, antigenically unique emergent strains; and furthers our understanding of genogroup II, genotype 4 (GII.4) norovirus immune-driven molecular evolution.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24648459      PMCID: PMC4054459          DOI: 10.1128/JVI.00203-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Evolution of human calicivirus RNA in vivo: accumulation of mutations in the protruding P2 domain of the capsid leads to structural changes and possibly a new phenotype.

Authors:  Mikael Nilsson; Kjell-Olof Hedlund; Margareta Thorhagen; Göran Larson; Kari Johansen; Anders Ekspong; Lennart Svensson
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

2.  Epidemiologic and molecular trends of "Norwalk-like viruses" associated with outbreaks of gastroenteritis in the United States.

Authors:  Rebecca L Fankhauser; Stephan S Monroe; Jacqueline S Noel; Charles D Humphrey; Joseph S Bresee; Umesh D Parashar; Tamie Ando; Roger I Glass
Journal:  J Infect Dis       Date:  2002-06-10       Impact factor: 5.226

3.  Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity.

Authors:  Kari Debbink; Lisa C Lindesmith; Eric F Donaldson; Veronica Costantini; Martina Beltramello; Davide Corti; Jesica Swanstrom; Antonio Lanzavecchia; Jan Vinjé; Ralph S Baric
Journal:  J Infect Dis       Date:  2013-08-01       Impact factor: 5.226

4.  Expression and self-assembly of norwalk virus capsid protein from venezuelan equine encephalitis virus replicons.

Authors:  Ralph S Baric; Boyd Yount; Lisa Lindesmith; Patrick R Harrington; Shermalyn R Greene; Fan-Chen Tseng; Nancy Davis; Robert E Johnston; David G Klapper; Christine L Moe
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

5.  Recombination within the pandemic norovirus GII.4 lineage.

Authors:  John-Sebastian Eden; Mark M Tanaka; Maciej F Boni; William D Rawlinson; Peter A White
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

6.  Proposal for a unified norovirus nomenclature and genotyping.

Authors:  Annelies Kroneman; Everardo Vega; Harry Vennema; Jan Vinjé; Peter A White; Grant Hansman; Kim Green; Vito Martella; Kazuhiko Katayama; Marion Koopmans
Journal:  Arch Virol       Date:  2013-04-25       Impact factor: 2.574

7.  Natural history of human calicivirus infection: a prospective cohort study.

Authors:  Barry Rockx; Matty De Wit; Harry Vennema; Jan Vinjé; Erwin De Bruin; Yvonne Van Duynhoven; Marion Koopmans
Journal:  Clin Infect Dis       Date:  2002-07-10       Impact factor: 9.079

8.  Emergence of a norovirus GII.4 strain correlates with changes in evolving blockade epitopes.

Authors:  Lisa C Lindesmith; Verónica Costantini; Jesica Swanstrom; Kari Debbink; Eric F Donaldson; Jan Vinjé; Ralph S Baric
Journal:  J Virol       Date:  2012-12-26       Impact factor: 5.103

9.  Integrating influenza antigenic dynamics with molecular evolution.

Authors:  Trevor Bedford; Marc A Suchard; Philippe Lemey; Gytis Dudas; Victoria Gregory; Alan J Hay; John W McCauley; Colin A Russell; Derek J Smith; Andrew Rambaut
Journal:  Elife       Date:  2014-02-04       Impact factor: 8.140

10.  Emergence of the GII-4 Norovirus Sydney2012 strain in England, winter 2012-2013.

Authors:  David J Allen; Natalie L Adams; Farah Aladin; John P Harris; David W G Brown
Journal:  PLoS One       Date:  2014-02-13       Impact factor: 3.240

View more
  32 in total

Review 1.  Emergence of norovirus strains: A tale of two genes.

Authors:  Gabriel I Parra
Journal:  Virus Evol       Date:  2019-11-25

2.  Mapping broadly reactive norovirus genogroup I and II monoclonal antibodies.

Authors:  Sue E Crawford; Nadim Ajami; Tracy Dewese Parker; Noritoshi Kitamoto; Katsuro Natori; Naokazu Takeda; Tomoyuki Tanaka; Baijun Kou; Robert L Atmar; Mary K Estes
Journal:  Clin Vaccine Immunol       Date:  2014-11-26

Review 3.  What is the reservoir of emergent human norovirus strains?

Authors:  Stephanie M Karst; Ralph S Baric
Journal:  J Virol       Date:  2015-03-18       Impact factor: 5.103

4.  Norovirus in health care and implications for the immunocompromised host.

Authors:  Pearlie P Chong; Robert L Atmar
Journal:  Curr Opin Infect Dis       Date:  2019-08       Impact factor: 4.915

5.  Vaccination-induced herd immunity: Successes and challenges.

Authors:  Michael L Mallory; Lisa C Lindesmith; Ralph S Baric
Journal:  J Allergy Clin Immunol       Date:  2018-05-24       Impact factor: 10.793

6.  RNA populations in immunocompromised patients as reservoirs for novel norovirus variants.

Authors:  Everardo Vega; Eric Donaldson; Jeremy Huynh; Leslie Barclay; Ben Lopman; Ralph Baric; Luke F Chen; Jan Vinjé
Journal:  J Virol       Date:  2014-10-01       Impact factor: 5.103

Review 7.  Developments in understanding acquired immunity and innate susceptibility to norovirus and rotavirus gastroenteritis in children.

Authors:  Daniel C Payne; Umesh D Parashar; Benjamin A Lopman
Journal:  Curr Opin Pediatr       Date:  2015-02       Impact factor: 2.856

8.  Norovirus vaccines and potential antinorovirus drugs: recent advances and future perspectives.

Authors:  Jacob Kocher; Lijuan Yuan
Journal:  Future Virol       Date:  2015       Impact factor: 1.831

Review 9.  Norovirus in Transplantation.

Authors:  Michael P Angarone; Anna Sheahan; Mini Kamboj
Journal:  Curr Infect Dis Rep       Date:  2016-06       Impact factor: 3.725

Review 10.  Human norovirus transmission and evolution in a changing world.

Authors:  Miranda de Graaf; Janko van Beek; Marion P G Koopmans
Journal:  Nat Rev Microbiol       Date:  2016-05-23       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.